Butylphthalide + Butylphthalide placebo
Phase 3Recruiting 1 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
ST-segment Elevation Myocardial Infarction (STEMI)
Conditions
ST-segment Elevation Myocardial Infarction (STEMI)
Trial Timeline
Dec 1, 2024 → Dec 31, 2025
NCT ID
NCT06704685About Butylphthalide + Butylphthalide placebo
Butylphthalide + Butylphthalide placebo is a phase 3 stage product being developed by CSPC Pharmaceutical Group Limited for ST-segment Elevation Myocardial Infarction (STEMI). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06704685. Target conditions include ST-segment Elevation Myocardial Infarction (STEMI).
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06704685 | Phase 3 | Recruiting |
Competing Products
1 competing product in ST-segment Elevation Myocardial Infarction (STEMI)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| dual antiplatelet therapy (aspirin + ticagrelor or aspirin + clopidogrel) | Shenzhen Salubris Pharmaceuticals | Pre-clinical | 22 |